Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636204 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
A Phase 1 study of Healthy and Frontotemporal Dementia, sponsored by Alector.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 8
- Study locations
NCT03636204 is a Phase 1 study of Healthy and Frontotemporal Dementia that has completed, run by Alector. The registered enrollment target is 64 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT03636204, a Phase 1 study of Healthy and Frontotemporal Dementia, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 8
- Study locations
Study Summary
A first in human phase 1 study in healthy volunteers and participants with Granulin (GRN) mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AL001
Study Locations (8)
Other
- Sunnybrook Health Sciences Centre - Toronto
- University College London - London
Alabama
- University of Alabama - Birmingham
California
- UCSF - San Francisco
Florida
- Study site - Orlando
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Ontario
- Lawson Health Research Institute, St. Joseph's - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636204
The ClinicalTrials.gov registry entry for NCT03636204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03636204 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03636204 about?
NCT03636204 is a clinical study titled "A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation". A first in human phase 1 study in healthy volunteers and participants with Granulin (GRN) mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics
What is the current status of trial NCT03636204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2018-09-14. Estimated completion is 2019-12-31.
What conditions does trial NCT03636204 study?
This clinical trial studies the following conditions: Healthy, Frontotemporal Dementia.
What interventions are being tested in trial NCT03636204?
The interventions under investigation include: Placebo (OTHER), AL001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03636204?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03636204 being conducted?
This trial has 8 study locations across Alabama, California, Florida, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.